Matthew F Challman

Matthew Challman is an MD/PhD candidate at the Icahn School of Medicine at Mount Sinai whose research focuses on neuroimmune mechanisms driving neurodegeneration, with an emphasis on how microglial functional states respond to Alzheimer’s disease amyloid pathology. In the Schaefer Lab, he has identified molecular pathways, including CD28 expression on microglia and Polycomb Repressive Complex 2-dependent regulation of TREM2 signaling, that shape microglial interactions with amyloid plaques. This work was supported by a Ruth L. Kirschstein NRSA (F30) fellowship. He plans to pursue residency training in neurology and a career as a physician-scientist dedicated to advancing the understanding and treatment of neurodegenerative disorders.